Archive
1250 articles, sorted by publication time.
The deal secures two preclinical antibody-drug conjugates and an NMT inhibitor platform with an $1.1 billion upfront payment; whether activity in drug-resistant models can translate into efficacy in humans will determine the value of this sizable early-stage investment.
Z-rostudirsen uses an antibody fragment to improve tissue delivery of an oligonucleotide, and the FDA will decide by January 2027 whether to grant accelerated approval; the real test is whether increased dystrophin can translate into lasting improvements in physical function.
The Firelink platform uses antibodies to carry targeted protein degraders in an effort to address difficult-to-drug targets in solid tumors; the transaction has been completed, but efficacy, safety, and candidate drug progress remain undisclosed.
Off-the-shelf NKX019 is now being administered at community trial sites, in an effort to bring highly specialized cell therapy into more accessible outpatient settings; however, safety, efficacy, and community sites’ ability to deliver the treatment still need to be addressed by early-stage trials.
Alumis announced preliminary results from a Phase 3 extension trial: among patients who continued taking envudeucitinib, 54% achieved PASI 100 at Week 48. Efficacy appears to deepen over time, but full data, comparative analyses, and long-term safety details have yet to be disclosed.
Researchers have identified a molecular switch that coordinates stress responses, RNA clearance, and cellular dedifferentiation; however, shutting it down may not only suppress cancer, but could also force tumors toward more heterogeneous cell fates.
From shortening research sequencing times to bringing complex mass spectrometry into routine laboratories, Roche presented a blueprint for easing workforce pressures through automation and data integration; however, several products still lack independent performance data, and some are not yet available for clinical use.
Building on a rare molecular population beyond lung and thyroid cancers, this precision therapy has completed the regulatory transition from accelerated to traditional approval with tumor-agnostic response data extending for nearly two years.
By simultaneously suppressing two B-cell survival signals, atacicept targets IgA nephropathy and has been approved to reduce proteinuria in high-risk adult patients; the approval also shifts the competitive focus further upstream toward the disease’s immune mechanisms.
The acquisition of AtaiBeckley gives Lilly immediate access to clinical pipelines for 5-MeO-DMT and DMT; however, the additional $1 billion in consideration remains tied to trial progress, FDA approval, and rescheduling of controlled substances in the United States.
A regional review assessed clinical trials, collaboration payments actually received, and third-party validation using the same yardstick. The results show that AI has helped move some drug candidates into human studies, but “AI-discovered” is still not a single, clearly defined scientific label.
The companies will integrate genomic, imaging, and clinical data to identify targets, design therapies, and build R&D agent tools. However, what has been announced so far remains a platform and organizational blueprint, with no drug candidates or experimental validation available for evaluation.